Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

Neoplasia (United States)

Volumn 17, Issue 2, 2015, Pages 190-200

  Lee, Jasmine G ^a   Wu, Reen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CAPILLARY DENSITY; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE; ADENOCARCINOMA; ANIMAL; APOPTOSIS; DRUG EFFECTS; GENETICS; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; LUNG TUMOR; METABOLISM; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; ERLOTINIB HYDROCHLORIDE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MYC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84989325558     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.12.008     Document Type: Article

References (67)

1. [1] Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N Engl J Med 359 (2008), 1367–1380.
2. [2] Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., André, F., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006), 983–991.
3. [3] Tsang, R.Y., Al-Fayea, T., Au, H.J., Cisplatin overdose: toxicities and management. Drug Saf 32 (2002), 1109–1122.
4. [4] Zhang, Z., Kobayashi, S., Borczuk, A.C., Leidner, R.S., Laframboise, T., et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31 (2010), 577–586.
5. [5] Brabender, J., Danenberg, K.D., Metzger, R., Schneider, P.M., Park, J., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 (2001), 1850–1855.
6. [6] Zhang, X., Chang, A., Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5 (2008), 209–217.
7. [7] Kosaka, T., Yamaki, E., Mogi, A., Kuwano, H., Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol, 2011, 16524.
8. [8] Oxnard, G.R., Arcila, M.E., Chmielecki, J., Ladanyi, M., Miller, V.A., et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17 (2011), 5530–5537.
9. [9] Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
10. [10] Kobayashi, S., Boggon, T.J., Dayaram, T., Jänne, P.A., Kocher, O., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005), 786–792.
11. [11] Zhang, Z., Lee, J.C., Lin, L., Olivas, V., Au, V., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44 (2012), 852–860.
12. [12] Kwak, E.L., Sordella, R., Bell, D.W., Godin-Heymann, N., Okimoto, R.A., et al. Irreversible inhibitors of the egf receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102 (2005), 7665–7670.
13. [13] Morgillo, F., Kim, W.Y., Kim, E.S., Ciardiello, F., Hong, W.K., et al. Implication of the insulin-like growth factor-ir pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13 (2007), 2795–2803.
14. [14] Habib, A.A., Chun, S.J., Neel, B.G., Vartanian, T., Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor mediated signal transduction pathways. Mol Cancer Res 1 (2003), 219–233.
15. [15] Elkind, N.B., Szentpétery, Z., Apáti, A., Ozvegy-Laczka, C., Várady, G., et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65 (2005), 1770–1777.
16. [16] Pirazzoli, V., Nebhan, C., Song, X., Wurtz, A., Walther, Z., et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 7 (2014), 999–1008.
17. [17] Galanski, M., Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 1 (2006), 285–295.
18. [18] Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., et al. Molecular mechanisms of cisplatin resistance. Oncogene 31 (2012), 1869–1883.
19. [19] Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 2003, 7265.
20. [20] Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., et al. EGFR-pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283 (2007), 739–750.
21. [21] Huang, W.C., Chen, Y.J., Hung, M.C., Implication of nuclear EGFR in the development of resistance to anticancer therapies. Biomedicine 1 (2011), 2–10.
22. [22] Rodemann, H.P., Dittmann, K., Toulany, M., Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83 (2007), 781–791.
23. [23] Guerreiro, S.G., Brochhausen, C., Negrão, R., Barbosa, M.A., Unger, R.E., Kirkpatrick, C.J., et al. Implanted neonatal human dermal fibroblasts influence the recruitment of endothelial cells in mice. Biomatter 2 (2012), 43–52.
24. [24] Herbst, R.S., Onn, A., Sandler, A., Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23 (2005), 3243–3256.
25. [25] Lu, Y.Y., Jing, D.D., Xu, M., Wu, K., Wang, X.P., Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 14 (2009), 5403–5411.
26. [26] Mahller, Y.Y., Vaikunth, S.S., Currier, M.A., Miller, S.J., Ripberger, M.C., et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 15 (2007), 279–286.
27. [27] Kong, C., Zhu, Y., Sun, C., Li, Z., Sun, Z., et al. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 65 (2005), 395–399.
28. [28] Shen, F.Z., Wang, J., Liang, J., Mu, K., Hou, J.Y., et al. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?. Int J Exp Pathol 91 (2010), 10–16.
29. [29] Lee, J.G., Wu, R., Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PLoS One, 7, 2012, e48532.
30. [30] Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58 (2006), 621–681.
31. [31] Deshpande, N., Ren, Y., Foygel, K., Rosenberg, J., Willmann, J.K., Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology 258 (2011), 804–811.
32. [32] Figueras, A., Arbos, M.A., Quiles, M.T., Viñals, F., Germà, J.R., et al. The impact of KRAS mutations on VEGF-A production and tumour vascular network. BMC Cancer, 13, 2013, 125.
33. [33] Goddard, J.C., Sutton, C.D., Furness, P.N., Kockelbergh, R.C., O'Byrne, K.J., A computer image analysis system for microvessel density measurement in solid tumours. Angiogenesis 5 (2002), 15–20.
34. [34] Lobo, E.D., Balthasar, J.P., Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci 92 (2003), 1654–1664.
35. [35] Goudar, R.K., Vlahovic, G., Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 10 (2008), 277–282.
36. [36] Poon, E., Harris, A.L., Ashcroft, M., Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med, 11, 2009, e26.
37. [37] Zhang, J., Sattler, M., Tonon, G., Grabher, C., Lababidi, S., et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1α–dependent pathway in multiple myeloma. Cancer Res 69 (2009), 5082–5090.
38. [38] Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007), 169–181.
39. [39] Zhang, Z., Stiegler, A.L., Boggon, T.J., Kobayashi, S., Halmos, B., EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1 (2010), 497–514.
40. [40] Castillo, L., Etienne-Grimaldi, M.C., Fischel, J.L., Formento, P., Magné, N., et al. Pharmacological background of EGFR targeting. Ann Oncol 15 (2004), 1007–1012.
41. [41] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
42. [42] Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
43. [43] Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004), 13306–13311.
44. [44] Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005), 123–132.
45. [45] Hirsch, F.R., Varella-Garcia, M., Bunn, P.A. Jr., Franklin, W.A., Dziadziuszko, R., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006), 5034–5042.
46. [46] Zwitter, M., Rajer, M., Kovac, V., Kern, I., Vrankar, M., et al. Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial. J Biomed Biotechnol, 2011, 2011, 185646.
47. [47] Okabe, T., Okamoto, I., Tsukioka, S., Uchida, J., Hatashita, E., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 15 (2009), 907–913.
48. [48] Minami, D., Takigawa, N., Takeda, H., Takata, M., Ochi, N., et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 11 (2013), 140–148.
49. [49] Diep, C.H., Munoz, R.M., Choudhary, A., Von Hoff, D.D., Han, H., Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res 17 (2011), 2744–2756.
50. [50] Yamamoto, C., Basaki, Y., Kawahara, A., Nakashima, K., Kage, M., et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 70 (2010), 8715–8725.
51. [51] Suda, K., Tomizawa, K., Osada, H., Maehara, Y., Yatabe, Y., et al. Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 76 (2012), 292–299.
52. [52] Suda, K., Mizuuchi, H., Maehara, Y., Mitsudomi, T., Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny. Cancer Metastasis Rev 31 (2012), 807–814.
53. [53] Gridelli, C., Rossi, A., Maione, P., New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 60 (2006), 76–86.
54. [54] Meert, A.P., Paesmans, M., Martin, B., Delmotte, P., Berghmans, T., et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87 (2002), 694–701.
55. [55] Lu, H., Klein, R.S., Schwartz, E.L., Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap. Clin Cancer Res 15 (2009), 5136–5144.
56. [56] Yun, S.M., Jung, K.H., Lee, H., Son, M.K., Seo, J.H., et al. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Lett 331 (2013), 250–261.
57. [57] Verheul, H.M., Salumbides, B., Van Erp, K., Hammers, H., Qian, D.Z., et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14 (2008), 3589–3597.
58. [58] Brand, T.M., Iida, M., Li, C., Wheeler, D.L., The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12 (2011), 419–432.
59. [59] Jaganathan, S., Paladino, D.C., Bogdanovic, J., Huo, Q., Turkson, J., A functional nuclear epidermal growth factor receptor, SRC and stat3 heteromeric complex in pancreatic cancer cells. PLoS One, 6, 2011, e19605.
60. [60] Jaganathan, S., Yue, P., Turkson, J., Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther 333 (2010), 373–381.
61. [61] Biroccio, A., Benassi, B., Amodei, S., Gabellini, D., Del Bufalo, D., et al. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 60 (2001), 174–182.
62. [62] Osborne, C., Wilson, P., Tripathy, D., Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9 (2004), 361–377.
63. [63] Kim, H.E., Kim, D.G., Lee, K.J., Son, J.G., Song, M.Y., et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One, 7, 2012, e43223.
64. [64] Xie, Q., Bradley, R., Kang, L., Koeman, M., Ascierto, M.L., et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 109 (2012), 570–575.
65. [65] Slinker, B.K., The statistics of synergism. J Mol Cell Cardiol 30 (1998), 723–731.
66. [66] Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361 (2009), 958–967.
67. [67] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.